These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 24989175)
1. Improvement of a woman's alcohol-related dementia via off-label memantine treatment: a 16-month clinical observation. Bonnet U; Taazimi B; Borda T; Grabbe HD Ann Pharmacother; 2014 Oct; 48(10):1371-5. PubMed ID: 24989175 [TBL] [Abstract][Full Text] [Related]
2. The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia. Cheon Y; Park J; Joe KH; Kim DJ Int J Neuropsychopharmacol; 2008 Nov; 11(7):971-83. PubMed ID: 18346293 [TBL] [Abstract][Full Text] [Related]
3. [Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia]. Litvinenko IV; Odinak MM; Mogil'naia VI; Perstenev SV Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(10):37-42. PubMed ID: 19008850 [TBL] [Abstract][Full Text] [Related]
4. [Alcoholism and aging. 2. Alcoholic dementia or alcoholic cognitive impairment?]. Pierucci-Lagha A; Derouesné C Psychol Neuropsychiatr Vieil; 2003 Dec; 1(4):237-49. PubMed ID: 15683959 [TBL] [Abstract][Full Text] [Related]
5. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Diehl-Schmid J; Förstl H; Perneczky R; Pohl C; Kurz A Int J Geriatr Psychiatry; 2008 Jul; 23(7):754-9. PubMed ID: 18213609 [TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled study of memantine (Ebixa) in dementia of Wernicke-Korsakoff syndrome. Rustembegović A; Kundurović Z; Sapcanin A; Sofic E Med Arh; 2003; 57(3):149-50. PubMed ID: 12858653 [TBL] [Abstract][Full Text] [Related]
7. Visual hallucinations treated with the reinitiation of memantine in a patient with Lewy body dementia. Mathys ML; McCarrell J; Sleeper RB; Blaszczyk AT Ann Pharmacother; 2013 Feb; 47(2):e10. PubMed ID: 23386073 [TBL] [Abstract][Full Text] [Related]
8. [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina]. Rojas G; Demey I; Arizaga RL Medicina (B Aires); 2013; 73(3):213-23. PubMed ID: 23732196 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of Drug-Induced Xerostomia in Older Adults with Cognitive Impairment or Dementia: An Observational Study. Gil-Montoya JA; Barrios R; Sánchez-Lara I; Carnero-Pardo C; Fornieles-Rubio F; Montes J; Gonzalez-Moles MA; Bravo M Drugs Aging; 2016 Aug; 33(8):611-8. PubMed ID: 27438469 [TBL] [Abstract][Full Text] [Related]
10. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R; Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological enhancing agents targeting cognition in patients with alcohol-induced neurocognitive disorders: A systematic review. Mistarz N; Andersen K; Nielsen AS; Goudriaan AE; Michel TM; Skøt L; Nielsen DG; Mellentin AI Neurosci Biobehav Rev; 2021 Jun; 125():608-626. PubMed ID: 33667552 [TBL] [Abstract][Full Text] [Related]
13. Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: a pilot study. Pelton GH; Harper OL; Roose SP; Marder K; D'Antonio K; Devanand DP Int J Geriatr Psychiatry; 2016 Jun; 31(6):648-55. PubMed ID: 26559790 [TBL] [Abstract][Full Text] [Related]
14. A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence. Buckley JS; Salpeter SR Drugs Aging; 2015 Jun; 32(6):453-67. PubMed ID: 25941104 [TBL] [Abstract][Full Text] [Related]
15. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Görtelmeyer R; Erbler H Arzneimittelforschung; 1992 Jul; 42(7):904-13. PubMed ID: 1418054 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. Wang HF; Yu JT; Tang SW; Jiang T; Tan CC; Meng XF; Wang C; Tan MS; Tan L J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):135-43. PubMed ID: 24828899 [TBL] [Abstract][Full Text] [Related]
17. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Hartmann S; Möbius HJ Int Clin Psychopharmacol; 2003 Mar; 18(2):81-5. PubMed ID: 12598818 [TBL] [Abstract][Full Text] [Related]
18. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Swanberg MM Alzheimer Dis Assoc Disord; 2007; 21(2):164-6. PubMed ID: 17545743 [TBL] [Abstract][Full Text] [Related]
19. [A comparison of the efficacy and safety of memantal and original memantine in the treatment of mild and moderate dementia in Alzheimer's disease]. Shiryaev OY; Shapovalov DL; Polozova TM; Goncharova OV; Kuznetsova NA; Cherenkova EV; Fedorova EY Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):56-61. PubMed ID: 26525623 [TBL] [Abstract][Full Text] [Related]